 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...3435363738394041424344...266267» |
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Phase II Study of Nivolumab Plus Ipilimumab with Chemotherapy for Advanced NSCLC with Untreated Brain Metastases: NIke Trial (LOGiK2004) (405A) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1131;
This study met the primary endpoint and treatment with a nivolumab-ipilimumab combined with platinum-based chemotherapy yielded promising intracranial response in patients with untreated brain metastases derived from NSCLC.Clinical trial information: jRCTs071210019
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227 (405A) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1094;
P3
Nivolumab + ipilimumab continued to provide long-term, durable efficacy benefit vs chemotherapy in patients with tumor PD-L1 ?1% or <1% (a population with high unmet need). Responders with higher tumor burden reduction had greater long-term OS benefit with nivolumab + ipilimumab vs chemotherapy.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial (Summit 1) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1007;
Neoadjuvant dual immunotherapy and concurrent chemoradiotherapy resulted in very high MPR and pCR rates, did not interfere with pulmonary resection, and no excess in early morbidity and mortality was observed when compared to previous institutional cohorts treated with CRT alone. Longer follow-up to assess toxicity, as well as translational analyses regarding the immunological effects of this induction scheme, are needed in order to interpret the clinical potential of this approach in (borderline) resectable NSCLC.Characteristics of evaluable patients in the INCREASE trialn (n%)Sex (male:female)11:14Age (years, median (iqr))64 (55-69)HistologyAdenocarcinoma12 (48%)Squamous cell carcinoma7 (28%)Large-cell NOS5 (20%)Large-cell neuroendocrine1 (4%)Tumor stage (8th TNM edition)Stage IIB T3N05 (20%)Stage IIIA T3N14 (16%)Stage IIIA T4N012 (48%)Stage IIIA T4N13 ((12%)Stage IIIB T3N21 (4%)Invasive mediastinal staging None3 (12%)EBUS17 (68%)EUS2 (8%)EBUS+EUS2 (8%)Mediastinoscopy1 (4%)Radiotherapy dose50Gy22 (88%)60Gy3 (12%)Time from last radiotherapy to surgery (days, median (iqr))43 (41-44)Chest wall invasion11 (44%)Sulcus superior tumors7Other4Pulmonary resectionLobectomy13 (52%)Lobectomy + thoracic wall10 (40%)Lobectomy + thoracic wall + partial vertebrectomy1 (4%)Pneumonectomy1 (4%)Resection margin R025 (100%)Pathological responsepCR15 (60%)MPR19 (76%)No MPR6 (24%)Postoperative morbidityAny grade16 (64%)Grade 1-211 (44%)Grade 3-45 (20%)Wound dehiscence1 (+readmission <30days)Atelectasis2Pancreatitis1Empyema1 (+readmission <30days)Hospital stay (days, median (iqr))6 (5-9)NOS = not otherwise specified, iqr = interquartile range, EBUS = endobronchial bronchial ultrasound,EUS = esophageal ultrasound, Gy = Gray, R0 = radical resection margin, pCR = pathological complete response,MPR = major pathological response
- Australian Registry and Biobank of Thoracic Cancers (AURORA) - A Multi-Site Research Platform and Longitudinal Cohort Study (Nicoll 3) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_984;
The prospective cohort provides highly granular information to completement clinical quality and population registries. It provides value to investigators through data ownership, flexible contribution and networking for research collaborations, and to industry through cost-effective targeted real-world investigations.
- Keytruda (pembrolizumab) / Merck (MSD), anetumab ravtansine (BAY 94-9343) / Bayer
Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma - NCT03126630 (Summit 2) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_962;
P1/2
There were no differences in confirmed response rates between patients treated with the combination of anetumab ravtansine and pembrolizumab, or pembrolizumab alone. The confirmed response rates were lower than reported previously reported for pembrolizumab in pleural mesothelioma.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The Addition of Multisite SBRT to Ipilimumab and Nivolumab in First Line Metastatic NSCLC: The COSINR Trial (405A) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_844;
In a population enriched for negative PDL1 expression, overall outcomes were encouraging with a median OS of 34 months. Further prospective study is warranted; radiomic and plasma correlative analysis is planned to help guide selection.
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Metastases: A phase III trial shows a significantly longer progression-free survival with cabozantinib, nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma https://t.co/56sBZy4Nov @BianchiniGP @CarmenCriscit @mauricallari (Twitter) - Jul 25, 2023
- || Review, Journal, Checkpoint inhibition, Checkpoint block: The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. (Pubmed Central) - Jul 24, 2023
Ongoing trials are studying the combination of LAG-3 antibodies with PD-1 inhibitors in multiple cancers and settings. The low toxicity of the combination may also allow for further layering of additional therapeutic approaches such as chemotherapy, oncolytic viruses, cellular therapies, and possibly novel cytokines, among others.
- || Tibsovo (ivosidenib) / Servier
Trial primary completion date: Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma (clinicaltrials.gov) - Jul 22, 2023
P1/2, N=92, Not yet recruiting, Sponsor: Servier Bio-Innovation LLC
The low toxicity of the combination may also allow for further layering of additional therapeutic approaches such as chemotherapy, oncolytic viruses, cellular therapies, and possibly novel cytokines, among others. Trial primary completion date: Nov 2023 --> Mar 2026
- | Opdivo (nivolumab) / BMS, BMS-986156 / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Tumor mutational burden: BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (clinicaltrials.gov) - Jul 21, 2023
P1/2, N=68, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2023 --> Mar 2026 Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma (clinicaltrials.gov) - Jul 21, 2023
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024 Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- | CIML NK - Dana / Farber Cancer Institute
Trial primary completion date, Combination therapy, Metastases, Immune cell: CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) - Jul 20, 2023
P1, N=12, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Trial primary completion date: Jun 2023 --> Sep 2023
- | Trial completion date: Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (clinicaltrials.gov) - Jul 20, 2023
P1, N=36, Recruiting, Sponsor: Carlo Contreras
Trial primary completion date: Jun 2023 --> Sep 2023 Trial completion date: Dec 2024 --> Dec 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date: Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma (clinicaltrials.gov) - Jul 20, 2023
P2, N=50, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Dec 2024 --> Dec 2025 Trial completion date: Jul 2023 --> Jul 2024
- ||| tobemstomig (RG6139) / Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, Trial completion date, Trial primary completion date: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov) - Jul 20, 2023
P1/2, N=336, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jul 2023 --> Jul 2024 N=191 --> 336 | Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Nov 2023 --> Oct 2024
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date: Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (clinicaltrials.gov) - Jul 20, 2023
P1, N=73, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=191 --> 336 | Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Nov 2023 --> Oct 2024 Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jan 2023
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition: Regression of a melanoma brain metastasis that had appeared after immune checkpoint inhibitor discontinuation: a hypothesis-generating case. (Pubmed Central) - Jul 19, 2023
Follow-up imaging showed a sustained response, although the patient did not receive any other oncological treatment. We discuss here the potential immune mechanisms involved in this unusual course and the importance of better understanding the behaviour of tumours in the era of ICIs.
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: #TumorBoardTuesday Sequencing agents is such an important q! How would you approach situation in 1L where pt is ECOG 0-1 w no impending clinical crisis? Ipi/nivo -> TKI on progression? Or start w IO + TKI -> TKI? (Twitter) - Jul 18, 2023
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal: Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. (Pubmed Central) - Jul 17, 2023
This article will summarize BsAbs targeting CTLA-4, their applications in cancer immunotherapy, and relevant clinical trial advances. We will also discuss the pre-clinical rationale for using these BsAbs, and provide the current landscape of the field.
- | Journal, PD(L)-1 Biomarker, IO biomarker: Adjuvant therapy for stage II melanoma: the need for further studies. (Pubmed Central) - Jul 17, 2023
We will also discuss the pre-clinical rationale for using these BsAbs, and provide the current landscape of the field. In the metastatic setting, patients treated with nivolumab and ipilimumab have an expected 5-year survival of>
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, IO biomarker, Immunomodulating: Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. (Pubmed Central) - Jul 17, 2023
The association between rs7036417 and IPI irAEs in our data suggests a role of SYK overexpression in irAE development. These findings support the hypothesis that inherited variation in immune-related pathways modulates ICI toxicity and suggests SYK as a possible future target for therapies to reduce irAEs.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Circulating tumor DNA: Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis. (Pubmed Central) - Jul 17, 2023
ctDNA represents a promising biomarker for monitoring response to treatment in advanced STS, warranting future prospective studies. Combining cryotherapy and immune checkpoint inhibitors did not increase the response rate of STSs to immunotherapy.
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (clinicaltrials.gov) - Jul 17, 2023
P2, N=40, Recruiting, Sponsor: Dan Zandberg
Combining cryotherapy and immune checkpoint inhibitors did not increase the response rate of STSs to immunotherapy. Trial completion date: Mar 2026 --> Aug 2029 | Trial primary completion date: Mar 2025 --> Aug 2029
- || Clinical, Retrospective data, Review: Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis. (Pubmed Central) - Jul 16, 2023
Certainly, more head-to-head studies are needed to confirm these findings. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022373291.
- | Journal, Checkpoint inhibition, IO biomarker, Metastases: Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma. (Pubmed Central) - Jul 14, 2023
Rare patients with BRAF fusions or rearrangements had decreased progression-free and overall survival following initial immunotherapy. Other BRAF, NRAS, or NF1 mutations were not associated with significant differences in outcome.
- | Trial completion date, Trial primary completion date, IO biomarker: MEMBRAINS: Melanoma Metastasized to the Brain and Steroids (clinicaltrials.gov) - Jul 13, 2023
P2, N=80, Recruiting, Sponsor: Inge Marie Svane
Other BRAF, NRAS, or NF1 mutations were not associated with significant differences in outcome. Trial completion date: Jun 2025 --> Jun 2028 | Trial primary completion date: Jun 2023 --> Jun 2024
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial primary completion date: Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer (clinicaltrials.gov) - Jul 13, 2023
P2, N=101, Completed, Sponsor: Parker Institute for Cancer Immunotherapy
Trial completion date: Jun 2025 --> Jun 2028 | Trial primary completion date: Jun 2023 --> Jun 2024 Active, not recruiting --> Completed | N=220 --> 101 | Trial primary completion date: Mar 2023 --> Jun 2023
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Monotherapy: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (clinicaltrials.gov) - Jul 12, 2023
P3, N=1390, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=220 --> 101 | Trial primary completion date: Mar 2023 --> Jun 2023 Trial completion date: Jul 2023 --> Aug 2027
- | Opdivo (nivolumab) / BMS, Aliqopa (copanlisib) / Bayer, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment closed, Checkpoint inhibition, IO biomarker: Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (clinicaltrials.gov) - Jul 12, 2023
P1/2, N=102, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2023 --> Aug 2027 Recruiting --> Active, not recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors (clinicaltrials.gov) - Jul 12, 2023
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Clinical, Monotherapy, Metastases: While I agree with importance of disease burden, I don’t really see the point of comparing outcomes of 58 pts in KN564 treated with complete metastasectomy and pembro monotherapy vs metastatic cosmic313 pts treated with ipi/nivo/cabo as an ‘argument’ for this… (Twitter) - Jul 12, 2023
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Real-world evidence, Real-world, Metastases: Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma. (Pubmed Central) - Jul 11, 2023
No difference was observed in OS although these data were immature. Larger studies are needed to further interrogate the social and economic determinants of ethnicity on clinical outcomes in mRCC.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: Good news! I wonder how the arm of ipi+nivo did in this trial A chemo free regimen as first line mUC with positive results would be great. (Twitter) - Jul 11, 2023
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, IO biomarker: CheckMate 9LA: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (clinicaltrials.gov) - Jul 10, 2023
P3, N=719, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Larger studies are needed to further interrogate the social and economic determinants of ethnicity on clinical outcomes in mRCC. Trial completion date: Jan 2023 --> Jan 2024
- | Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Jul 10, 2023
P2/3, N=600, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2023 --> Jan 2024 Trial completion date: Jun 2033 --> Aug 2023 | Trial primary completion date: Jun 2033 --> Aug 2023
- ||||| Clinical, Metastases: Great presentation by our colleague and friend @boutrosand on 2nd day of this Young @AIOMtweet 2023 on melanoma. 🔎 focus on: 1. mRNA vaccine + Pembro promising adjuvant therapy 2. IPI+NIVO 1st standard line even in BRAFm 3. Tebentafusp standard tp for uveal metastatic melanoma (Twitter) - Jul 8, 2023
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, IO biomarker: CheckMate 901: Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (clinicaltrials.gov) - Jul 7, 2023
P3, N=1290, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jun 2033 --> Aug 2023 | Trial primary completion date: Jun 2033 --> Aug 2023 Trial primary completion date: Jun 2023 --> Apr 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma (clinicaltrials.gov) - Jul 7, 2023
P1, N=18, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2023 --> Apr 2024 Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date: A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma (clinicaltrials.gov) - Jul 7, 2023
P2, N=2, Completed, Sponsor: University of Chicago
Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2024 Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Apr 2023 | Trial primary completion date: Feb 2025 --> Apr 2023
- | Opdivo (nivolumab) / BMS, Aliqopa (copanlisib) / Bayer, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma (clinicaltrials.gov) - Jul 6, 2023
P1, N=64, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Apr 2023 | Trial primary completion date: Feb 2025 --> Apr 2023 Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
- | Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 6, 2023
P1, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024 Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
- | New trial, Adverse events, Checkpoint inhibition: EXIT: EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database (clinicaltrials.gov) - Jul 6, 2023
P=N/A, N=141630, Active, not recruiting, Sponsor: Groupe Hospitalier Pitie-Salpetriere
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Clinical data, Journal, Checkpoint inhibition: International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. (Pubmed Central) - Jul 5, 2023
Conclusions ?We present findings from the largest cohort of SNMM reported to date. We demonstrate the potential utility of further stratifying the T3 stage by sinus involvement and present promising data on the benefit of immune checkpoint inhibitors for recurrent, persistent, or metastatic disease with implications for future clinical trials in this field.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations. (Pubmed Central) - Jul 5, 2023
We also explore the benefit of the combination schedule across different subgroups of patients and possible predictive biomarkers for efficacy outcomes in order to elucidate which patients could be the best candidates for combination or single-agent therapy. Patients with BRAF-mutant tumours, asymptomatic brain metastases, or PD-L1-negative status appear to reach better survival outcomes with the combination relative to single-agent immunotherapy.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Metastases: Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. (Pubmed Central) - Jul 5, 2023
PRD was strongly correlated with worse survival rates. LNM was independently associated with PRD in patients with mRCC receiving NIVO+IPI as first-line therapy and might indicate that a candidate will not benefit from NIVO+IPI.
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Tumor mutational burden, IO biomarker: CA224-056: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (clinicaltrials.gov) - Jul 5, 2023
P2, N=60, Recruiting, Sponsor: Robert Ferris
LNM was independently associated with PRD in patients with mRCC receiving NIVO+IPI as first-line therapy and might indicate that a candidate will not benefit from NIVO+IPI. Trial completion date: Aug 2026 --> Jul 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer (clinicaltrials.gov) - Jul 5, 2023
P=N/A, N=5, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Aug 2026 --> Jul 2025 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- ||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, IO biomarker: CheckMate743: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (clinicaltrials.gov) - Jul 5, 2023
P3, N=605, Completed, Sponsor: Bristol-Myers Squibb
Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 Active, not recruiting --> Completed
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, IO biomarker: CA209-6D9: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases (clinicaltrials.gov) - Jul 3, 2023
P1, N=24, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Initiation date: Jan 2023 --> Jun 2023
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors (clinicaltrials.gov) - Jul 3, 2023
P2, N=9, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Jan 2023 --> Jun 2023 Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024